Chronic hepatitis B infection, which is difficult to cure, is a recognized fact, and some people with bad intentions, one-sidedly exaggerating the effectiveness of their treatment, is to take advantage of the reality that slow hepatitis B is difficult to cure and the psychology of patients seeking to be cured, to deceive trust and money, however, should patients with chronic hepatitis B give up hope, we look at the views of some experts this year: March 12, 2015, the Asia-Pacific Association for the Study of the Liver ( APASL) chronic hepatitis B (CHB) guideline update call for papers was announced at the APASL Congress. The new version of the guideline describes CHB treatment endpoints in a tiered manner, emphasizing durable immune response after drug discontinuation as a higher pursuit. The three treatment endpoint levels are: 1. The ideal treatment endpoint is durable surface antigen clearance after drug discontinuation, which is often referred to as a negative “AoA”; 2. minor triple-positive), durable virologic response (undetectable hepatitis B viral DNA in serum) after drug discontinuation is a satisfactory endpoint; 3. If durable response after drug discontinuation is not available, sustained virologic remission (undetectable hepatitis B viral DNA) during antiviral therapy is an acceptable endpoint. The ideal is rich, but the reality is skeletal, the current situation of treatment in China is that the ideal and satisfactory treatment endpoints are very difficult to achieve, at present, most of our antiviral can only achieve an acceptable endpoint, there are five antiviral treatment drugs in China, the rate of hepatitis B viral DNA conversion after one year of treatment are: lamivudine 50-60%, adefovir 40-50%, tipifudine 70%, entecavir 80% for entecavir, and 90% for tenofovir. Tenofovir is not yet covered by health insurance and is unaffordable for most people. The best results can be achieved with 80% DNA conversion after one year of treatment with entecavir. The ideal endpoint is surface antigen regression, and the strongest combination therapy that has been reported is long-acting interferon combined with tenofovir, and a global, randomized, controlled, open study conducted by Marcellin, the first large-scale combination therapy study with surface antigen regression as the study endpoint, enrolled 740 patients with CHB, and showed that long-acting interferon PEG-IFN α-2a combined with tenofovir discontinued after 48 weeks of treatment, with a 9,0% clearance of hepatitis B surface antigen at follow-up to 72 weeks. In contrast, none of the patients on tenofovir disoproxil alone achieved surface antigen regression. A national multicenter randomized open study study (NEW SWITH) in China in 2014, for patients who did not achieve satisfactory endpoints after nucleoside (acid) analogue (NUC) therapy, switched to long-acting interferon PEG-IFNα-2a for 48 weeks: 1. The proportion of hepatitis B surface antigen quantification less than 1000 IU/ml could reach for 65, 7%, and the proportion of hepatitis B surface antigen quantification The proportion of hepatitis B surface antigen quantification less than 100 IU/ml can reach 46,5%; the proportion of hepatitis B surface antigen quantification less than 10 IU/ml can reach 25,7%; 2, the proportion of hepatitis B surface antigen clearance is 16,5%. For patients with surface antigen quantification of 1500 IU/ml and hepatitis B virus DNA conversion and e antigen clearance (this part of infected patients is called advantageous patients), the percentage of hepatitis B surface antigen clearance (cure, the ideal endpoint) after 48 weeks of long-acting interferon treatment can reach 31,2%. 3. Patients with viral load less than 200 IU/L and HbeAg conversion after nucleoside (acid) analog (NUC) treatment, who were switched to long-acting interferon treatment for 48 weeks, had 16,2% hepatitis B surface antigen conversion and 12,5% hepatitis B surface antibody conversion. The results of another study (OSST study) showed that for patients with viral load ≤103copeis/ml, E antigen conversion and surface antigen titers less than 1500 U/L after treatment with entecavir, switching to sequential treatment with long-acting interferon, the clearance rate of surface antigen could reach 25%. At 12 weeks of long-acting interferon therapy, surface antigen less than 200 U/L is predictive of optimal treatment efficacy at 48 weeks, and the clearance rate of hepatitis B surface antigen can be as high as 77,8% in such patients. . Therefore, the problem of curing chronic hepatitis B should no longer be easily said to be impossible, but should be subdivided to identify those patients with advantages to give more aggressive treatment, especially in most places, where long-acting interferon has been included in health insurance, and when economics is not an obstacle, more chronically infected patients should be allowed to enjoy the desired end point.